DOC1021 vaccine with SOC showed favorable 12-month OS in newly-diagnosed glioblastoma patients.
A New Brain Cancer Vaccine Shows Promise Where Other Treatments Fail
This Phase I clinical study evaluated DOC1021 (dubodencel) integrated with standard of care (SOC) in newly-diagnosed and recurrent glioblast…
A new type of personalized vaccine, added to standard treatment, was safe and linked to significantly longer survival for patients with a no…
AI-based PD-L1 scoring shows concordance with expert assessment in 333 NSCLC cases.
AI Now Reads Cancer Biopsies. Is It Better Than a Human Eye?
This cohort study evaluated concordance between AI-based PD-L1 scoring (uPath VENTANA PD-L1 Assay Algorithm) and expert pathologist assessme…
A new AI tool matches expert doctors in reading lung cancer biopsies, helping patients get faster, more consistent treatment decisions witho…
AM.score predicts lung adenocarcinoma outcomes and immunotherapy response in a cohort of 1,720 patients.
A Simple Blood Test Could Predict Your Lung Cancer Treatment Success
This preprint describes an observational cohort study involving 1,720 lung adenocarcinoma patients, with validation across additional cohort…
A new blood test score predicts which lung cancer patients will respond to immunotherapy, helping doctors avoid ineffective treatments for a…
Linvoseltamab shows improved outcomes versus real-world standard of care in relapsed/refractory multiple myeloma
New Hope for Myeloma Patients After Three Failed Treatments
A Phase 1/2 study with an external control arm compared linvoseltamab to real-world standard of care in 105 triple-class exposed or refracto…
Patients with multiple myeloma who failed three prior treatments show higher response rates and longer survival with linvoseltamab compared …
PINK1 expression quantified by IHC in adults with newly diagnosed IDH-wild type glioblastoma multiforme
A Simple Brain Tumor Test Could Predict Your Treatment Path
This prospective observational cohort study evaluated PINK1 expression in adults (18+ years) with newly diagnosed IDH-wild type glioblastoma…
A specific protein in glioblastoma tissue could forecast survival odds, helping patients plan care even though the test is not available yet…
Anti-BCMA CAR T-cell therapy bb21217 with bb007 showed 69.4% response in relapsed multiple myeloma.
Memory Cells Make CAR T Last Longer
This Phase I study evaluated anti-B-cell maturation antigen CAR T-cell therapy bb21217 manufactured with the phosphoinositide 3-kinase inhib…
CAR T cells trained to act like long-term guards may keep multiple myeloma away for years instead of burning out quickly after initial treat…
Accelerometer-derived circadian behavior patterns show attenuated associations with colorectal cancer risk after adjustment
Your Fitness Tracker May Hint at Colon Cancer Risk — Sort Of
A prospective cohort study of 95,050 UK Biobank participants examined 224 accelerometer-derived metrics and colorectal cancer incidence over…
How hard and continuously you move, not just total steps, may lower colorectal cancer risk, but the link weakens when accounting for other l…
Pathologic features predict rapid recurrence in T1 melanoma patients across 14 sites.
Why Thin Melanomas Kill Older Adults
This observational review analyzed 442 patients with T1 melanoma from 14 sites to identify predictors of rapid recurrence. Significant assoc…
Doctors now know that thin melanomas can be deadly for older adults if they return within two years, requiring closer monitoring than previo…
FDA Approves Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for PSMA-positive metastatic castration-resistant prostate cancer.
FDA approves a new treatment for advanced prostate cancer called Pluvicto.
The FDA has approved Pluvicto, a radioligand therapeutic agent, for the treatment of adult patients with PSMA-positive metastatic castration…
FDA approves Pluvicto, a targeted radiation therapy for advanced prostate cancer that has spread and stopped responding to standard hormone …
FDA Approves Ondansetron Injection, USP (ondansetron hydrochloride) for Prevention of Chemotherapy-Induced and Postoperative Nausea/Vomiting
FDA approves a new preservative-free injection to prevent nausea and vomiting from chemotherapy and surgery.
FDA approved ondansetron injection for prevention of nausea/vomiting associated with emetogenic cancer chemotherapy and postoperative nausea…
FDA approves a new preservative-free injection to prevent nausea and vomiting from chemotherapy and surgery.
Digital and AI-supported psychosocial interventions modestly reduce distress and improve quality of life in women with breast cancer.
Digital mental health tools may help breast cancer patients feel better
This systematic review and meta-analysis of randomized controlled trials evaluated digital and AI-supported psychosocial interventions in wo…
Digital mental health tools using AI and mindfulness help breast cancer patients reduce stress, anxiety, and depression while improving dail…
Adjuvant immune checkpoint inhibitors after curative HCC treatment associated with reduced recurrence risk
Adjuvant Immune Checkpoint Inhibitors May Reduce Liver Cancer Recurrence Risk
A meta-analysis of 3,478 patients with curatively treated hepatocellular carcinoma found adjuvant immune checkpoint inhibitor-based treatmen…
Adding immune checkpoint inhibitors after surgery or ablation significantly lowers the risk of liver cancer returning, giving patients a str…